Comparing late 2025 ulcerative colitis data across Eli Lilly’s mirikizumab (Omvoh), Abivax’s obefazimod, and Protagonist Therapeutics’ icotrokinra: evolving standards in long-term and oral IL-23 pathway–targeted therapy

Scheduled for:Oct 20, 2026 8:00 PM EDT

Call Duration:30 minutes

Desired Expert

To analyze and contextualize the October 2025 wave of pivotal ulcerative colitis (UC) readouts—from Lilly’s four-year LUCENT-3 mirikizumab extension, Abivax’s ABTECT Phase 3 induction data for obefazimod, and Protagonist’s ANTHEM-UC Phase 2b results for oral icotrokinra. The discussion will explore how these programs redefine durability, convenience, and depth of remission across biologic and oral classes, and what they reveal about the next phase of IL-23–centered and immunoregulatory strategies in inflammatory bowel disease.

Interview Goal

To analyze and contextualize the October 2025 wave of pivotal ulcerative colitis (UC) readouts—from Lilly’s four-year LUCENT-3 mirikizumab extension, Abivax’s ABTECT Phase 3 induction data for obefazimod, and Protagonist’s ANTHEM-UC Phase 2b results for oral icotrokinra. The discussion will explore how these programs redefine durability, convenience, and depth of remission across biologic and oral classes, and what they reveal about the next phase of IL-23–centered and immunoregulatory strategies in inflammatory bowel disease.

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.